Home
>
US Stocks
>
Verona Pharma Plc - ADR
Verona Pharma Plc - ADR
VRNA

Verona Pharma Plc - ADR (VRNA)

$5.130.39%

  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open$5.17
Today Low/High$5.13 / $5.17
52 Week Low/High$4.45 / $9.72
Market Cap$306.79M

Company Details

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma's product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE ('Ensifentrine as a Novel inHAled Nebulized COPD thErapy') for COPD maintenance treatment. The Company raised gross proceeds of $200 million through a private placement in July 2020 and expects the funds to support its operations and Phase 3 clinical program into 2023. Two additional formulations of ensifentrine are currently in Phase 2 development for the treatment of COPD: dry powder inhaler ('DPI') and pressurized metered-dose inhaler ('pMDI'). Ensifentrine is being evaluated in a pilot clinical study in patients hospitalized with COVID-19 and has potential applications in cystic fibrosis, asthma and other respiratory diseases.
OrganisationVerona Pharma Plc - ADR
Headquaters3 More London Place, London, United Kingdom
Employees26
IndustryHealth Technology
CEODavid Zaccardelli

Discover more

Frequently Asked Questions

What is Verona Pharma Plc - ADR (VRNA) share price today?

Can Indians buy Verona Pharma Plc - ADR (VRNA) shares?

How can I buy Verona Pharma Plc - ADR (VRNA) shares from India?

Can Fractional shares of Verona Pharma Plc - ADR (VRNA) be purchased?

What are the documents required to start investing in Verona Pharma Plc - ADR (VRNA) stocks?

We are a SEBI registered investement advisor